Preclinical discovery research of E7080, an inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) family of tyrosine kinases

被引：0
|
作者：
Funahashi, Yasuhiro [1 ]
机构：
[1] Eisai & Co Ltd, Oncol PCU, Discovery, Tsukuba, Ibaraki 3002635, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2010年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：33P / 33P
页数：1
相关论文
共 50 条
  • [1] Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
    Tohyama, Osamu
    Matsui, Junji
    Kodama, Kotaro
    Hata-Sugi, Naoko
    Kimura, Takayuki
    Okamoto, Kiyoshi
    Minoshima, Yukinori
    Iwata, Masao
    Funahashi, Yasuhiro
    JOURNAL OF THYROID RESEARCH, 2014, 2014
  • [2] Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases
    Singh, Harprit
    Milner, Christopher S.
    Hernandez, Maria M. Aguilar
    Patel, Nisha
    Brindle, Nicholas P. J.
    CELLULAR SIGNALLING, 2009, 21 (08) : 1346 - 1350
  • [3] Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
    Bruheim, Skjalg
    Kristian, Alexandr
    Uenaka, Toshimitsu
    Suo, Zhenhe
    Tsuruoka, Akihiko
    Nesland, Jahn M.
    Fodstad, Oystein
    INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (03) : 742 - 750
  • [4] The Effect of Rifampin On the Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor
    Cotreau, M.
    Subic, D.
    Massmanian, L.
    Strahs, A.
    Vargo, D.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 183 - 183
  • [5] Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
    Morabito, Alessandro
    Piccirillo, Maria Carmela
    Falasconi, Fabiano
    De Feo, Gianfranco
    Del Giudice, Antonia
    Bryce, Jane
    Di Maio, Massimo
    De Maio, Ermelinda
    Normanno, Nicola
    Perrone, Francesco
    ONCOLOGIST, 2009, 14 (04): : 378 - 390
  • [6] Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
    Cui, J
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (05) : 713 - 718
  • [7] Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080: a modeling and simulation approach
    Keizer, R. J.
    Gupta, A.
    Karlsson, M. O.
    Wanders, J.
    Jansen, M.
    Beijnen, J. H.
    Schellens, J. H. M.
    Huitema, A. D. R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 144 - 144
  • [8] The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on BRAF wild-type melanoma.
    Funahashi, Y.
    Matsui, J.
    Minoshima, Y.
    Yokoi, A.
    Abe, T.
    Okamoto, K.
    Takahashi, K.
    Kadowaki, T.
    Kuznetsov, G.
    Agoulink, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
    Anthony El-Khoueiry
    James A. Posey
    Juan Ramón Castillo Ferrando
    Smitha S. Krishnamurthi
    Shariq Syed
    Georgia Kollia
    Ian Walters
    Bruce S. Fischer
    Eric Masson
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 53 - 64
  • [10] The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
    El-Khoueiry, Anthony
    Posey, James A.
    Castillo Ferrando, Juan Ramon
    Krishnamurthi, Smitha S.
    Syed, Shariq
    Kollia, Georgia
    Walters, Ian
    Fischer, Bruce S.
    Masson, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 53 - 64
12345